Albert
Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies
Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns
Pfizer Prepared to Shift Manufacturing to US in Response to Potential Trump Tariffs
Pfizer, Albert Bourla, US manufacturing, Trump tariffs, pharmaceutical industry, reshoring
Pfizer’s European Manufacturing Vulnerable to Potential US Tariffs, CEO Warns
Pfizer, Albert Bourla, European manufacturing, US tariffs, pharmaceutical industry, trade tensions, supply chain disruption
Pfizer CEO Albert Bourla to Engage with Activist Investor Starboard Value on Strategic Overhaul
Pfizer, Albert Bourla, Starboard Value, activist investor, pharmaceutical industry, strategic overhaul, post-COVID challenges
Pfizer’s Former Executives Back Activist Investor Starboard’s Revamp Plan
Pfizer, Starboard Value, activist investor, Ian Read, Frank D’Amelio, Albert Bourla, pharmaceutical industry, corporate governance